Abstract
Drug-eluting stenting (DES) has become a reliable tool for coronary stenting; however, its direct effects on platelet and endothelium function differ from those of bare-metal stenting (BMS). This study involved a periprocedural analysis of various biomarkers of cellular activation after elective DES (Xience(®), Abbott Vascular, Santa Clara, CA, USA) or BMS (Integrity(®), Medtronic, Minneapolis, MI, USA). Forty-nine stable angina patients were recruited: 28 underwent BMS, and 21 received everolimus-eluting stents. Samples were collected (i) prior to stenting, (ii) at 24 hours after procedure, and (iii) after 1 month of dual antiplatelet therapy. Platelet activation was analyzed by surface P-selectin positivity in parallel with plasma levels of soluble P-selectin, CD40L and platelet-derived growth factor (PDGF). Endothelial cell (EC) activation was detected by measuring markers of early (von Willebrand factor) and delayed response (VCAM-1, ICAM-1, E-selectin). Patients were followed for 6 months for the occurrence of restenosis or stent thrombosis. Increased platelet activation was sustained regardless of stent type or antiplatelet medication. Concentrations of most EC markers were more elevated after BMS than after DES. No stent...Continue Reading
References
Jun 22, 2000·Heart·Y HojoK Shimada
Jul 7, 2001·European Heart Journal·T O'MalleyK A Fox
Mar 13, 2002·Journal of Internal Medicine·V Mohamed-AliJ H Pinkney
Oct 3, 2003·The New England Journal of Medicine·Jeffrey W MosesUNKNOWN SIRIUS Investigators
Jun 3, 2004·European Heart Journal·Antonio Colombo, Ioannis Iakovou
Jul 12, 2005·Thrombosis Research·Gennaro SardellaMarino Paroli
May 9, 2006·The American Journal of Cardiology·C Michael GibsonUNKNOWN TIMI Study Group
Aug 25, 2006·Platelets·Tibor SzükJános Kappelmayer
Jan 31, 2007·The American Journal of Cardiology·Robert J ApplegateWilliam C Little
Oct 26, 2007·Atherosclerosis·K VargováI Preda
Dec 15, 2007·Chest·Christopher J BoosGregory Y H Lip
May 24, 2008·Journal of the American College of Cardiology·Peter W GroeneveldFeifei Yang
Sep 4, 2008·Journal of Thrombosis and Thrombolysis·Ailiman MahemutiJean-Pierre Bassand
Jan 6, 2009·The American Journal of Cardiology·Manesh R PatelUNKNOWN APEX-AMI Investigators
May 26, 2009·JACC. Cardiovascular Interventions·Brian HorstAmir Lerman
Jan 1, 2008·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Steve RamcharitarPatrick W Serruys
Jan 7, 2010·Platelets·Béla NagyJános Kappelmayer
Apr 8, 2010·Journal of Thrombosis and Thrombolysis·Peter S MunkAlf I Larsen
Apr 24, 2010·Seminars in Thrombosis and Hemostasis·Rory R Koenen, Christian Weber
Aug 19, 2010·Toxicologic Pathology·Jun ZhangThomas Colatsky
Oct 13, 2010·Expert Review of Cardiovascular Therapy·Bimmer E ClaessenJan J Piek
Nov 23, 2010·Clinical Cardiology·Erick D McNairKailash Prasad
Dec 7, 2010·The American Journal of Cardiology·Francesco De FeliceRoberto Violini
Feb 18, 2011·Circulation. Cardiovascular Interventions·Steven O MarxAndrew R Marks
Jul 12, 2011·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Alexander SheehyIgor Polyakov
Oct 6, 2011·Circulation. Cardiovascular Interventions·Raul LlanoRobert L Wilensky
Nov 23, 2011·Anesthesia and Analgesia·Alisa S WolbergKellie R Machlus
Dec 30, 2011·Current Medicinal Chemistry·B NagyJ Kappelmayer
Apr 3, 2012·The American Journal of Cardiology·Laurent FauchierDominique Babuty
Apr 25, 2012·Archives of Internal Medicine·Giuseppe De LucaUNKNOWN Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation
Sep 3, 2013·European Heart Journal·UNKNOWN Task Force MembersJose Luis Zamorano
Dec 24, 2013·Thrombosis Research·Sarolta LeéRóbert G Kiss
Sep 1, 2014·European Heart Journal·Stephan WindeckerAdam Witkowski
Dec 3, 2014·International Journal of Cardiology·Alfonso IelasiMaurizio Tespili
Dec 3, 2014·International Journal of Cardiology·Shanmugam UthamalingamJames Flynn